Conference item
Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: efficacy and safety in the phase III randomized factorial AspECT Trial
- Abstract:
- Esophageal adenocarcinoma (EA) is the sixth most common cause of global cancer death. We rely on endoscopy screening to identify and monitor patients with Barrett’s esophagus (BE) and find neoplastic lesions early enough to manage their EA. This approach has a modest effect on EA supported by low quality evidence. We evaluated the efficacy of aspirin and high dose acid suppression in preventing EA in patients with BE.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 186.1KB, Terms of use)
-
- Publisher copy:
- 10.1200/JCO.2018.36.18_suppl.LBA4008
Authors
- Publisher:
- American Society of Clinical Oncology
- Host title:
- American Society of Clinical Oncology Annual Meeting (ASCO 2018)
- Journal:
- American Society of Clinical Oncology Annual Meeting (ASCO 2018) More from this journal
- Publication date:
- 2018-06-07
- Acceptance date:
- 2018-03-30
- DOI:
- Pubs id:
-
pubs:833458
- UUID:
-
uuid:5985fce4-d77e-49c0-a32d-b242d7312718
- Local pid:
-
pubs:833458
- Source identifiers:
-
833458
- Deposit date:
-
2018-04-04
Terms of use
- Copyright holder:
- American Society of Clinical Oncology
- Copyright date:
- 2018
- Notes:
- © 2018 American Society of Clinical Oncology. This is the accepted version of the abstract. The final version is available online from American Society of Clinical Oncology at: https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA4008
If you are the owner of this record, you can report an update to it here: Report update to this record